Clinical Trial

A Study of GR1803 Injection Versus Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Participants With Relapsed or Refractory Multiple Myeloma

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to compare the efficacy of GR1803 Injection with daratumumab in combination with pomalidomide and dexamethasone (DPd).
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-02-28.
Status change: Not Yet Recruiting → Recruiting 2026-03-23
Trial Details
NCT Number NCT07452198
Lead Sponsor Genrix (Shanghai) Biopharmaceutical Co., Ltd.
Conditions Multiple Myeloma
Enrollment 358 participants
Start Date 2026-03-09
Primary Completion 2029-03 (estimated)
Study Completion 2030-03 (estimated)
Updated on ClinicalTrials.gov 2026-03-25